BioMarin just got good news from the FDA for a treatment of an ultra-rare disorder. But with a price tag of $702000 a year, is a drug price debate waiting in the …
source CNBC
BioMarin CEO: Rare Treatments, High Costs | Mad Money | CNBC
BioMarin just got good news from the FDA for a treatment of an ultra-rare disorder. But with a price tag of $702000 a year, is a drug price debate waiting in the …
source CNBC
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More